獅子山集團(01127.HK)耗資1489.247萬港元收購合共118.5萬股Quarto股份
格隆匯1月7日丨獅子山集團(01127.HK)宣佈,於2021年8月6日至2022年1月6日期間,公司間接全資附屬公司匯星印刷於倫敦證券交易所公開市場收購合共 118.5萬股Quarto股份,總代價約為 140.495萬英鎊(相當於約 1489.247萬港元)(不包括印花税及相關開支),即每股Quarto股份的平均價格約為 1.19 英鎊(相當於約12.57港元)。
緊接公開市場收購及 2021 收購事項前,匯星印刷持有Quarto已發行股本約36.7%。緊接公開市場收購及 2021 收購事項後,匯星印刷持有Quarto已發行股本約 43.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.